The aseptic pharmaceutical processing market is growing incredibly quickly. This strong and sustained performance is being fuelled by greater demand for sterile drug products. A factor that is driving this growth is the way in which modern therapies have changed the approach to helping patients. As with any significant shift in process, any changes that are implemented need to be ones that are functional in the long term, especially in today’s rapidly changing environment. Christian Dunne of ChargePoint Technology explores the latest trends in containment and advises how pharma companies can adapt and thrive in a fast-evolving environment.

Extract:

‘How to Future-Proof the Manufacture of Sterile Drug Products’

The aseptic pharmaceutical processing market is growing incredibly quickly – in fact it is projected to develop from $62.2 billion in 2020 to $73.6 billion by 2027.

This strong and sustained performance is being fuelled by greater demand for sterile drug products. To illustrate, the generic sterile injectable market is predicted to grow at a compound annual growth rate of 11.3% moving from 2020 to 2030 to reach a value of $198.7bn .

A factor that is driving this growth is the way in which modern therapies have changed their approach to helping patients. There has been a shift towards more targeted therapies, which has resulted in products being produced in smaller batch sizes. This is increasingly true in aseptic processing and that means pharma manufacturers have to consider how to produce these products efficiently and cost-effectively at a smaller scale. This has significant implications for manufacturers, who have to rethink how facilities are designed and re-assess capex spending.

As with any significant shift in process, any changes that are implemented need to be ones that are functional in the long-term, especially in today’s rapidly changing environment. This can only be achieved by first assessing the principal challenges facing manufactures involved in aseptic processing.

The challenges faced

The pharma industry is operating in an increasingly complex environment. The shift towards personalised treatments often means that it is not cost-efficient option for drug developers to build out facilities specific to each treatment, with all of the associated capex spending. In turn, this has led to greater outsourcing of many stages of the manufacturing process that has resulted in a more fragmented supply chain.

Click the download button below to read the complete version of ‘How to Future-Proof the Manufacture of Sterile Drug Products’ by Christian Dunne of ChargePoint Technology